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Background: Familial chylomicronemia syndrome (FCS) is a rare lipid disease caused by complete lipoprotein lipase
(LPL) deficiency resulting in fasting chylomicronemia and severe hypertriglyceridemia. Inhibition of diacylglycerol
acyltransferase 1 (DGAT1), which mediates chylomicron triglyceride (TG) synthesis, is an attractive strategy to reduce
TG levels in FCS. In this study we assessed the safety, tolerability and TG-lowering efficacy of the DGAT1 inhibitor
pradigastat in patients with FCS.
Methods: Six FCS patients were enrolled in an open-label clinical study. Following a 1-week very low fat diet run-in
period patients underwent baseline lipid assessments, including a low fat meal tolerance test. Patients then underwent
three consecutive 21 day treatment periods (pradigastat at 20, 40 & 10 mg, respectively). Treatment periods were
separated by washout periods of ≥4 weeks. Fasting TG levels were assessed weekly through the treatment periods.
Postprandial TGs, ApoB48 and lipoprotein lipid content were also monitored.
Results: Following once daily oral dosing, steady-state exposure was reached by Day 14. There was an approximately
dose proportional increase in pradigastat exposure at studied doses. Pradigastat was associated with a 41% (20 mg)
and 70% (40 mg) reduction in fasting triglyceride over 21 days of treatment. The reduction in fasting TG was almost
entirely accounted for by a reduction in chylomicron TG. Pradigastat treatment also led to substantial reductions in
postprandial TG as well as apo48 (both fasting and postprandial). Pradigastat was safe and well tolerated, with only
mild, transient gastrointestinal adverse events.
Conclusion: The novel DGAT1 inhibitor pradigastat substantially reduces plasma TG levels in FCS patients, and may be
a promising new treatment for this orphan disease.
Trial registration: ClinicalTrials.gov identifier NCT01146522.
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In response to a fat containing meal, chylomicrons (CM)
are secreted by small intestine enterocytes into the
bloodstream where they deliver dietary triglyceride (TG)
to body tissues such as skeletal muscle and adipose. In
most humans, CM-TG is rapidly cleared from the blood-
stream by the enzyme lipoprotein lipase (LPL), which
hydrolyzes the TG into free fatty acids, which are then
taken up into the skeletal muscle or adipose for energy* Correspondence: dan.meyers@novartis.com
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unless otherwise stated.utilization or storage. Familial chylomicronemia syndrome
(FCS), also known as type I hyperlipoproteinemia, is a rare
autosomal recessive disease caused by loss-of-function mu-
tations in the LPL gene or by mutations in genes encoding
proteins or enzymes directly affecting LPL activity [1]. The
complete loss of LPL activity significantly decreases the
clearance of CM-TG, leading to CM accumulation in both
the fed and fasted states (i.e. chylomicronemia), and severe
hypertriglyceridemia [2,3].
Clinical signs and symptoms of FCS include recurrent ep-
isodes of abdominal pain, lactescent plasma, lipemia retina-
lis, skin lesions (eruptive xanthomas), hepatosplenomegaly,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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chemical and hematological laboratory values [1]. Most im-
portantly, FCS patients are at a very high risk of developing
acute pancreatitis, which can be severe and life-threatening
and is associated with high medical costs [4]. Chronic pan-
creatitis, pancreatic insufficiency, and cardiometabolic com-
plications may also occur in patients with FCS [1]. Genetic
LPL defects have also been associated with an increased
risk of pulmonary embolism or atelectasia [5].
The primary therapeutic goal in FCS patients is to re-
duce hypertriglyceridemia to decrease the risk of acute
pancreatitis. Unfortunately, currently available oral TG-
lowering drugs which up-regulate LPL activity and/or
down-regulate very-low-density lipoprotein (VLDL)-TG
synthesis typically have little to no efficacy in FCS pa-
tients [6]. Without effective oral pharmacotherapy, pa-
tients are required to observe a very low fat diet (≤15%
by calories) to lower their TG levels. Even with strict ad-
herence to the very low fat diet, which is difficult to
comply with for prolonged periods, TG levels are typically
difficult to control [7]. LPL gene replacement therapy has
recently been approved in Europe, although its use is cur-
rently restricted to the most severely affected patients with
FCS due to an LPL gene defect and recurrent pancreatitis
[8,9]. Its long-term efficacy is still under investigation.
Diacylglycerol acyltransferase-1 (DGAT1) catalyzes the
final step in TG synthesis and is highly expressed in the
small intestine enterocytes, where it plays a key role in
absorption of dietary fat [10]. DGAT1-deficient mice are
protected from the typical post-meal spike in plasma TG
levels, and have significantly decreased post meal levels
of CMs [11]. Based on this, DGAT1 inhibition is an at-
tractive strategy to reduce the synthesis and secretion of
CM-TG, and thereby lower total TG in FCS patients.
Pradigastat (formerly LCQ908) is a potent and selective
small-molecule DGAT1 inhibitor. Oral administration of
pradigastat showed the median Tmax of about 10 hours
which slowly declined with a prolonged terminal elimin-
ation half-life of ~150 hours [12,13]. Pradigastat de-
creased CM-TG synthesis and secretion in animals
resulting in blunted postprandial hypertriglyceridemia
[14]. In healthy human volunteers, pradigastat decreased
postprandial CM particle numbers and TG content, pre-
venting postprandial hypertriglyceridemia, and therefore
may be effective in lowering TG in patients with FCS [14].
The objective of this study was to assess the safety, tol-
erability, and effects of the DGAT1 inhibitor pradigastat
on fasting and postprandial plasma TG in patients with
FCS and severe hypertriglyceridemia.
Results
Patient characteristics and disposition
Six patients with genetically confirmed FCS were en-
rolled in the study (two males and four females, allCaucasian) with a mean (standard deviation [SD]) age of
51.5 (12.7) years. Mean height and weight of the patients
were 165.0 (8.8) cm and 59.4 (15.8) kg, respectively, and
mean body mass index was 21.5 (3.9) kg/m2. All the six
patients completed treatment periods 1 and 2, while four
patients completed period 3. Two patients withdrew
from the study after period 2 for personal scheduling
reasons. Individual demographic data is shown in
Table 1.
Effects on plasma triglycerides
Changes in mean fasting TG levels during the treatment
with pradigastat 10, 20, and 40 mg are shown in Table 2
and Figure 1. After 1-week dietary run-in period, geomet-
ric mean fasting TG level decreased from 3219.8 mg/dL
(36.18 mmol/L; CV%, 71.7) on Day −7 to 1892.9 mg/dL
(21.27 mmol/L; CV%, 31.8) on Day −1. Fasting TG level
fell by an additional 41% from Day −1 at the end of
21 days’ therapy with pradigastat 20 mg (65% reduction
from Day −7). During treatment period 2, there was a 70%
reduction in fasting TG with pradigastat 40 mg at Day 21
compared with Day −1. No reduction in fasting TG was
observed after 21-day treatment with pradigastat 10 mg
during treatment period 3.
Two patients receiving pradigastat 20 mg (n = 6) and
three patients receiving pradigastat 40 mg (n = 6) had
attained end-of-treatment fasting TG levels below
1000 mg/dL. Furthermore, four patients had ≥30% re-
duction in fasting TG, while one patient had ≥50% re-
duction after receiving pradigastat 20 mg. Reduction in
fasting TG with the 20 and 40 mg doses was statistically
significantly greater than that with the 10 mg dose (ratio
of geometric LS [Least Squares] mean ratio to baseline,
0.49 [90% confidence intervals [CI] 0.34–0.71] and 0.51
[90% CI 0.35–0.75], respectively; p < 0.01 for both). The
TG-lowering effects of the 20 and 40 mg doses were not
significantly different from each other (1.04 [90% CI
0.75–1.44], p = 0.83).
Changes in postprandial plasma TG levels during the
study are shown in Table 2. The baseline meal tolerance
test (MTT) led to TG levels of around ≈ 2000 mg/dL
(≈20 mmol/L) over 9 hours, with a slight increase in TG
levels between 2 and 6 hours. Overall, postprandial TG
during the entire MTT duration was higher with pradi-
gastat 10 mg compared to baseline MTT (Figure 2A).
Both peak postprandial TG value (−38%) and area under
the curve over the 9 hours (AUC0–9; −37%) were re-
duced with pradigastat 20 mg. Reduction in peak post-
prandial TG (−31%) and AUC0–9 (−30%) was also noted
with pradigastat 40 mg. Both the 20 and 40 mg doses
led to significantly lower AUC0–9 (Figure 2B) than the
10 mg dose (ratio of geometric LS mean ratio to baseline,
0.38 [90% CI 0.22–0.67] and 0.42 [90% CI 0.24–0.74], re-
spectively; p < 0.022 for both). Furthermore, three patients
Table 1 Patient demographics
Patient #1 Patient #2 Patient #3 Patient #4 Patient #5 Patient #6 Mean +/−SD
Age (years) 66 35 53 38 63 54 51.5 +/− 12.7
Weight (kg) 36.5 77.7 74.2 57.7 47.0 63.1 59.4 +/− 15.8
Height (cm) 159 175 175 162 153 166 165.0 +/− 8.8
BMI (kg/m2) 14.4 25.4 24.2 22.0 20.0 22.9 21.5 +/− 3.9
Gender Female Male Male Female Female Female -
All individuals were of the Caucasian race.
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AUC0–9 and two patients each had ≥50% reduction in the
same parameters with pradigastat 20 mg on reduction re-
sponse assessment.
Effects on apolipoprotein B48
Both fasting and postprandial plasma apolipoprotein
(ApoB48) levels decreased after treatment with pradiga-
stat at 20 and 40 mg doses (Table 2). Compared with the
10 mg dose, both 20 mg (ratio of geometric LS mean ra-
tio to baseline, 0.67 [90% CI 0.49–0.93], p = 0.051) and
40 mg (0.46 [90% CI 0.34–0.64], p = 0.002) doses were
associated with a significant decrease in fasting ApoB48.
Compared with the 20 mg dose, the 40 mg dose of pra-
digastat had a significant reduction in fasting ApoB48
(0.69 [90% CI 0.52–0.91], p = 0.035). In addition, both
the 20 and 40 mg doses significantly decreased the post-
prandial peak and AUC0–9 ApoB48 levels compared with
the 10 mg dose (Figure 3).
Effects on lipoprotein fractions and other parameters
Effects of pradigastat on lipoprotein fractions as arith-
metic means and the corresponding % change from
baseline are shown in Table 3. As expected, CMs
accounted for the majority of baseline total plasma TG
(≈90%) and cholesterol (≈75%). Compared with each
treatment period’s baseline, CM-TG content was consist-
ently reduced at all the dose levels. Furthermore, CMTable 2 Effects of pradigastat on fasting and postprandial tri
geometric means (CV %), unless otherwise specified
Baseline* Treatment period 1
Pradigastat 20 mg (n = 6)
EOT† Ratio‡
Fasting TG, mmol/L 19.21 (35.2) 12.80. (25.0) 0.67. (33.1
Peak PPTG, mmol/L 20.91. (27.0) 12.91. (29.4) 0.62. (27.8
AUC0–9 PPTG, h*mmol/L 163.49. (29.3) 103.16. (22.7) 0.63. (25.1
Fasting ApoB48, g/L 0.071. (51.3) 0.063. (41.6) 0.88. (25.5
Peak PP ApoB48, g/L 0.079. (34.1) 0.067. (39.7) 0.84. (23.8
AUC0–9 PP ApoB48, h*g/L 0.632. (36.2) 0.527. (39.9) 0.83. (22.1
ApoB48 = apolipoprotein B48; AUC0–9 = area under curve over 0 to 9 hours; CV = co
PP = postprandial; TG = triglycerides.
*Baseline values are at Day −1 for all the parameters, except for fasting TG and Apo
except for fasting TG and ApoB48 (mean of Day 21 and Day 22); ‡Geometric meancholesterol content was also reduced, with incremental
reductions on higher doses. Pradigastat had mixed ef-
fects on low-density lipoprotein (LDL) and VLDL lipid
content. Even with a modest increase in LDL-C seen at
the 20 mg dose, the absolute post-treatment LDL-C was
low (43.3 mg/dL). Pradigastat treatment generally in-
creased HDL lipid content (cholesterol in particular).
Pharmacokinetic assessment
With once daily dosing one hour before breakfast, pradi-
gastat appeared to achieve steady-state exposure by Day
14 as the dose normalized pre-dose concentrations ap-
pear to be comparable between Day 21 and Day 14.
There was an approximately dose proportional increase
in pradigastat exposure at studied doses. The maximal
plasma concentration was achieved by a median of 1–10
hours at steady-state across the study dose range. Mean
(SD) steady-state Cmax and AUCtau achieved for 10 mg,
20 mg, and 40 mg dose was 296 (111) ng/mL and 6,190
(2,660) ng*hr/mL, 950 (572) ng/mL and 18,000 (10,600)
ng*hr/mL, and 2,170 (1,300) ng/mL and 39,900 (24,100)
ng*hr/mL, respectively. Plasma concentration-time pro-
file of pradigastat on Day 21 is shown in Figure 4.
Safety and tolerability
Pradigastat was generally well tolerated in FCS patients
at daily doses up to 40 mg for 3 weeks. There were no
deaths or serious adverse events (SAEs) reported. Noneglyceride and apolipoprotein B48Data presented are
Treatment period 2 Treatment period 3
Pradigastat 40 mg (n = 6) Pradigastat 10 mg (n = 4)
EOT† Ratio‡ EOT† Ratio‡
) 13.97. (79.2) 0.73. (47.7) 32.14. (35.8) 1.41. (26.9)
) 14.38. (84.9) 0.69. (71.8) 41.22. (34.1)§ 1.69. (37.3)§
) 114.69. (79.7) 0.70. (65.8) 321.68. (36.5)§ 1.63. (37.9)§
) 0.043. (67.1) 0.61. (37.0) 0.113. (47.5) 1.29. (23.2)
) 0.048. (56.8) 0.61. (28.6) 0.149. (29.7)§ 1.53. (20.0)§
) 0.378. (63.1) 0.60. (33.3) 1.261. (30.7)§ 1.60. (16.2)§
efficient of variation; EOT = end of treatment;
B48 (mean of Day −1 and Day 1); †EOT values are at Day 21 for all parameters,
ratio to baseline; §n = 3.
Figure 1 Fasting triglyceride levels during the treatment with
pradigastat at different doses. Footnote: Data presented as
geometric mean ± standard error of mean (SEM).
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course of the study due to any adverse event (AE). A
total of 66 AEs were reported by the six patients during
the three treatment periods. All the AEs were mild to
moderate in severity. AEs reported by the patients are
shown in Table 4.
The most common AEs reported were gastrointestinal
events, including diarrhea, abdominal pain, and nausea.
These AEs were usually mild and self-limited. There
were no drug discontinuations or clinical evidence of
volume depletion or electrolyte imbalance. The gastro-
intestinal AE profiles were similar across the differentFigure 2 Postprandial plasma triglyceride levels during the treatment
geometric mean ± standard error of mean (SEM). Percentage change compar
TG, triglycerides; AUC0–9, area under curve over 0 to 9 hours of meal tole
Panel B = TG AUC0-9.doses administered to the FCS patients. Diarrhea of
moderate severity was reported for one day in only one
patient each during the 20 and 40 mg dosing periods.
There were no clinically significant abnormalities in
hematology, blood chemistry, vital signs, or electrocar-
diogram (ECG) parameters.
Discussion
Plasma TG levels are difficult to control in FCS patients,
and as a result these patients are at high risk of develop-
ing recurrent pancreatitis [1,15]. Even strict adherence
to very low fat diet is usually unsatisfactory [7]. Recently
adeno-associated virus type I LPL gene therapy was ap-
proved in Europe for the treatment of FCS in a subset of
patients with recurrent pancreatitis [9,16]. However, LPL
gene therapy is costly and requires multiple intramuscu-
lar injections performed under general anesthesia. None
of the currently available oral triglyceride lowering ther-
apies are effective in FCS patients. We show here, for
the first time, that the orally administered DGAT1 in-
hibitor pradigastat is associated with substantial reduc-
tions in plasma TG in FCS patients. This suggests that
pradigastat may be an effective oral treatment for FCS.
Pradigastat treatment over the course of 21 days was as-
sociated with up to a 70% reduction in fasting plasma
TG compared to baseline. Reductions of plasma TGs of
this magnitude are likely to be clinically meaningful in
FCS patients, as plasma TG levels typically correlate with
risk of acute pancreatitis and other complications such
as xanthomas. With the limited sample size of this study,
pradigastat appeared to achieve steady state exposure bywith pradigastat at different doses. Footnote: Data presented as
ed with the 10 mg dose for postprandial TG AUC0–9 are shown by ‘↓’.
rance test. Panel A = TG concentration/time profile over 9 hours,
Figure 3 Dose comparison of fasting and postprandial apolipoprotein B48 levels. Footnote: Original ApoB48 values were expressed in ng/L
for fasting and postprandial peak, and h*ng/mL for postprandial AUC0–9. This figure shows the Geometric least squares mean ratio of the end of
treatment for each of the three dose levels to baseline. Percentage change compared with the 10 mg dose are shown by ‘↓’; * p < 0.05.
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steady-state, exposure increased approximately dose-
proportional between 10, 20 and 40 mg doses.
Furthermore, pradigastat appeared to be safe in FCS
patients, with no treatment-induced clinically meaning-
ful abnormalities in safety laboratories, ECGs, or phys-
ical findings. Pradigastat treatment was associated with
mild and transient gastrointestinal AEs (most commonly
diarrhea) but these did not lead to any drug discontinu-
ation, or episodes of volume depletion. The very low fat
diet recommended for FCS patients appears to improve
the tolerability profile of DGAT1 inhibitors compared to
other studies with higher dietary fat content [17]. En-
rolled patients were all enthusiastic about their partici-
pation in the study, independent of the effect of
pradigastat on fasting plasma TG concentration. Erup-
tive xanthomas disappeared in two participants with
long history of very severe, hard-to-treat, xanthomatosis.Table 3 Mean change in lipid content of lipoprotein fractions
Treatment period 1 Treatment period
Pradigastat 20 mg (n = 6) Pradigastat 40 m
Baseline EOT % Change Baseline EO
CM-TG 22.11. (7.51) 8.95. (1.86) −59.5% 51.97. (49.78) 12
CM-C 5.38. (2.20) 3.32. (0.89) −38.3% 9.50. (6.28) 4.
LDL-TG 0.65. (0.22) 0.55. (0.21) −15.4% 1.33. (2.19) 0.
LDL-C 0.99. (0.34) 1.10. (0.25) 11.1% 1.01. (0.40) 1.
HDL-TG 0.25. (0.1) 0.27. (0.1) 8.0% 0.25. (0.10) 0.
HDL-C 0.34. (0.12) 0.55. (0.09) 61.7% 0.14. (0.13) 0.
VLDL-TG 2.75. (0.24) 2.40. (0.45) −12.7% 2.52. (1.45) 3.
VLDL-C 1.10. (0.56) 1.08. (0.28) −1.8% 0.51. (0.59) 1.
Data presented in mmol/L as arithmetic mean (SD) unless otherwise specified.
C = cholesterol; CM= chylomicrons; EOT = end of treatment; HDL = high-density lipopro
lipoprotein.
Arithmetic means are presented since geometric means could not be calculated forA detailed review of the patients’ perspective is actually
under investigation in this PoC study and in subsequent
phase III sub-study.
Pradigastat has been shown to substantially reduce the
rate of chylomicron-TG secretion into the lymphatic sys-
tem following an oral fat load in animals [14]. Further-
more, pradigastat decreases the size and TG content of
secreted chylomicrons. These effects are likely a result of
direct DGAT1 inhibition of the absorptive enterocytes of
the proximal small intestine, cells which absorb, re-
esterify and secrete dietary fatty acids as chylomicron
TG. Our findings that pradigastat reduces postprandial
TGs, decreases chylomicron TG content, and reduces
apoB48 levels in FCS patients are consistent with the hy-
pothesis that DGAT1 inhibition reduces chylomicron se-
cretion. This reduction of chylomicron-TG secretion
may relatively off-load non-LPL TG clearance mecha-
nisms in FCS patients, thus allowing previouslywith pradigastat
2 Treatment period 3
g (n = 6) Pradigastat 10 mg (n = 4)
T % Change Baseline EOT % Change
.64. (7.12) −75.7% 52.90. (10.11) 30.93. (13.48) −41.5%
38. (3.23) −53.9% 8.48. (2.91) 6.45. (3.46) −23.9%
36. (0.17) −72.9% 0.65 (0.17) 0.50. (0.29) −23.1%
02. (0.26) 1.0% 0.93. (0.39) 0.79 (0.19) −15.1%
22. (0.04) −12.0% 0.20. (0.08) 0.25. (0.06) 25.0%
46. (0.11) 228.6% 0.17. (0.21) 0.25. (0.14) 47.1%
06. (0.75) 21.4% 3.55. (1.53) 3.53. (1.62) −0.6%
40. (0.55) 63.6% 0.23. (0.25) 0.94. (0.45) 308.7%
tein; LDL = low-density lipoprotein; TG = triglycerides; VLDL = very-low-density
all parameters due to zero values.
Figure 4 Pradigastat plasma concentration-time profile. Footnote: Data presented as mean ± standard deviation.
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duction of TG by pradigastat was almost entirely a result
of the reduction in CM-TG, as VLDL-TG was mostly
unchanged (Table 3). In FCS patients, almost all plasma
TG is found in CM in both the fasted and fed state. This
is different than in healthy subjects, where VLDL con-
tains all the TG in the fasted state, while fed TG is gen-
erally split between CM and VLDL (and their remnants)
in the postprandial state. Further studies will be needed
to confirm that pradigastat decreases chylomicron-TG
secretion in FCS, and to elucidate the mechanism by
which fasting TG levels are decreased in these patients.
This exploratory study was conducted in a total of six
FCS patients from a founder population who share the
same underlying genetic defect in LPL. Although it isTable 4 Adverse events reported by the patients during prad
Adverse events,
n (%)
Treatment period 1 Treatme
Pradigastat 20 mg (n = 6) Pradiga
Diarrhea 4 (66.7) 5 (83.3)
Abdominal pain 3 (50.0) 2 (33.3)
Nausea 0 (0.0) 2 (33.3)
Flatulence 2 (33.3) 2 (33.3)
Abdominal pain upper 2 (33.3) 2 (33.3)
Fecal incontinence 1 (16.7) 0 (0.0)
Abdominal distension 1 (16.7) 0 (0.0)
Dizziness 0 (0.0) 1 (16.7)
Insomnia 1 (16.7) 1 (16.7)
Dyspepsia 1 (16.7) 0 (0.0)
Influenza 1 (16.7) 1 (16.7)
A patient with multiple occurrences of an adverse event is counted only once in aanticipated that pradigastat will have similar efficacy and
tolerability in FCS patients with other defects in LPL or
associated genes, this needs to be confirmed. Further-
more, the absence of a placebo control prevents a con-
clusive determination whether the end-of-treatment
reduction in TG was due entirely to pradigastat treat-
ment, or study design effects such as the low fat diet
contributed to the observed TG lowering. Evidence from
this and other studies suggest that the TG-lowering ef-
fects observed in this study were primarily mediated by
pradigastat. Previous studies have shown that optimal
out-patient low fat diet compliance in FCS patients can
reduce fasting TG levels only to about 2000 mg/dL
[1,18]. The one week low fat diet run-in in this present
study reduced fasting TG levels to ~1900 mg/dL,igastat treatment
nt period 2 Treatment period 3 Total
(n = 6)stat 40 mg (n = 6) Pradigastat 10 mg (n = 4)
3 (75.0) 6 (100.0)
1 (25.0) 4 (66.7)
1 (25.0) 2 (33.3)
3 (75.0) 4 (66.7)
0 (0.0) 2 (33.3)
0 (0.0) 1 (16.7)
0 (0.0) 1 (16.7)
0 (0.0) 1 (16.7)
0 (0.0) 1 (16.7)
0 (0.0) 1 (16.7)
0 (0.0) 2 (33.3)
category during each treatment period.
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curred before pradigastat treatment began. Furthermore,
despite the continued low fat diet given during the
21 days of treatment at the lowest and ineffective pradi-
gastat dose (10 mg), there was no additional lowering in
fasting TG level. This evidence suggests that pradigastat
treatment (and not the low fat diet) mediated the con-
tinued drop in fasting TG below 2000 mg/dL during
treatment at the 20 mg and 40 mg levels. A randomized,
double-blind, placebo-controlled study will be needed to
fully quantify the diet-independent TG-lowering effect
of pradigastat in FCS patients.
Conclusions
The DGAT1 inhibitor pradigastat, in addition to a very-
low-fat diet, was associated with substantial reductions
in fasting and postprandial TG in patients with FCS. In
addition to reducing total TGs, pradigastat also reduced
chylomicron TG content, and apoB48 levels. Pradigastat
was safe and generally well tolerated in this FCS patients
in this study. Based on the encouraging results of this
exploratory study, pradigastat is currently being studied
in a randomized, double-blind, placebo-controlled, phase
III study in FCS patients (Novartis Pharmaceuticals. A
randomized, double-blind, placebo controlled study to
assess efficacy, safety and tolerability of LCQ908 in sub-
jects with familial chylomicronemia syndrome. Clinical-
Trials.gov, NCT01514461).
Methods
The study was conducted from May 2010 to May 2011,
in compliance with Good Clinical Practice as outlined in
the principles of the Declaration of Helsinki. The study
was approved by the institutional review board/independ-
ent ethics committee and written informed consent was
obtained from all the participating patients. The study was
registered with ClinicalTrials.gov (NCT01146522).
Patients
FCS patients aged 18–75 years not on any lipid-lowering
medications for ≥8 weeks prior to enrolment were eli-
gible for the study. All subjects were recruited at a single
clinical site in Quebec, Canada, where there is a popula-
tion of FCS patients due to a founder effect [18]. To be
included, patients had to meet at least two of the fol-
lowing criteria: fasting TG ≥890 mg/dL (>10 mmol/L);
post-heparin plasma LPL activity ≤20% of normal; LPL
mass >5% and/or confirmed homozygote or compound
heterozygote mutations in LPL gene (null alleles) with
LPL mass >5% and LPL activity ≤20%. Pregnant/nursing
women and patients with uncontrolled diabetes or an ac-
tive pancreatitis episode within 1 month of enrollment
were excluded. No medication other than the study drug
was allowed from the first dosing until all of the studyevaluations were completed, except for medication that
may have been required to treat AEs or preexisting co-
morbidities.
Study design and treatments
This was an open-label, three-period, sequential treat-
ment study, with enrolled patients undergoing a 1-week
run-in period with low-fat (~20%) diet to stabilize TG
levels (Figure 5). Following this, pradigastat was admin-
istered orally once daily for three weeks in each of the
three periods in a non-randomized sequence at 20
(period 1), 40 (period 2), and 10 mg (period 3) doses.
During the treatment periods, patients remained on the
same low-fat diet. There was a drug washout period of
at least four weeks between each treatment period, dur-
ing which time the patients also observed a low-fat diet.
Study procedures
Following confirmation of eligibility, patients began the
study on Day-7 when the low-fat diet was instituted to
stabilize TG levels. On Days −3 and −2, patients were
provided with frozen standardized low-fat meals pre-
pared by a Chef in collaboration with a trained dietician
to ensure dietary compliance. In the morning of Day −1,
following an overnight fast, blood samples were col-
lected to assess a baseline fasting lipid profile, after
which a MTT was performed. A test meal with approxi-
mately 972 kcal, 13.5 g of lipids (≈13% of calories), 155 g
of carbohydrates (≈64%), and 56 g of proteins (≈23%)
was administered, and blood samples were collected fre-
quently through 10 hours (pre-dose, 1, 2, 3, 4, 5, 6, 8, 10).
Patients were discharged thereafter and asked to return to
the study site next morning (Day 1) for blood collection
24-hour post MTT. The baseline MTT occurred only at
the beginning of treatment period 1.
From Day 1 to Day 21 of period 1, all patients received
pradigastat 20 mg orally once daily approximately 1 hour
before breakfast on an outpatient basis. Fasting blood
samples were collected on Days 1, 7, 14, and 21 pre-
dose for assessment of plasma lipids. Safety and compli-
ance assessments were carried out at weekly clinic visits
and by telephone monitoring at select times in between
the visits. Patients filled in a meal diary during the base-
line and all subsequent study periods to confirm compli-
ance with the diet. On Day 21, an on-treatment MTT
was performed, identical to the one done on Day −1.
Following a 24 hour post-MTT blood draw on the
morning of Day 22, patients returned to their homes,
with instructions to continue the low-fat diet.
Following a washout period of at least four weeks, pa-
tients returned to the clinical site for the start of period
2, where they received pradigastat 40 mg a day for
21 days. As with period 1, blood samples were taken on
Days 1, 7, 14, and 21, and another MTT was
Figure 5 Study design.
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period of at least 4 weeks, patients returned for a third
and final treatment period with 10 mg pradigastat. As
with the other periods, fasting blood samples were taken
throughout the period, and a MTT was administered on
Day 21. Following the final 24 hour post-MTT blood
sample, patients returned to their home. An end of study
visit was performed at least 14 days after the final treat-
ment period ended. During washout periods, patients
did not receive study medication, thus allowing pradiga-
stat to be cleared from the plasma before the next treat-
ment period started. Additionally, patients were
instructed to maintain their usual low fat diet during the
washout period.
TG and other laboratory parameters’ assessments
Blood samples were analyzed for TG using an enzymatic
hydrolysis method utilizing a Synchron LX® System
(Beckman Coulter, Inc., Brea, CA, USA). Plasma was
fractionated at the Ecogene-21 lab into different lipopro-
tein fractions by sequential steps of density gradient
ultracentrifugation. The first ultracentrifugation step
separated chylomicron (CM) particles (Sf > 400) from
the rest of the plasma. Following removal of the CM
layer, additional ultracentrifugation steps separated the
plasma into sf < 400 fractions: very-low density lipopro-
tein, low-density lipoprotein, and high-density lipopro-
tein. Each fraction was collected by aspiration from the
top of the centrifuge tube. Each of the four lipoprotein
fractions (CM, VLDL, LDL and HDL) had the following
measurements were taken: TG and cholesterol (using
standard colorimetric methods) and Apoproteins by
nephelometry.
Pharmacokinetic assessments
Blood samples (2 mL) for pharmacokinetic evaluation
were collected by either direct venipuncture or an in-
dwelling cannula into EDTA-containing tubes on Days
1, 7 and 14 pre-dose and at the following time points on
Day 21: pre-dose, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours
post-dose. The pharmacokinetic parameters were deter-
mined using a non-compartmental method (s) thatincluded area under the concentration-time curve from
time zero to the end of dosing interval (0-24 h) (AUCtau),
highest concentration observed during a dosing interval at
steady-state (Cmax,ss) and the time to reach maximum
plasma drug concentration after single dose administra-
tion (Tmax).
Safety assessments
Safety assessments during the study included physical
examination; ECG; vital signs; standard clinical labora-
tory evaluations including hematology, blood chemistry,
and urinalysis; and AE and SAE monitoring. AEs were
evaluated by recording their onset, duration, severity, re-
lation to the therapy, and treatment required.
Statistical analysis
A dose comparison was carried out for fasting TG data,
which was analyzed using a linear mixed effect model
for repeated measurements. The model included treat-
ment, time, and treatment by time interaction as factors;
baseline as a covariate; and subject as a random effect.
Postprandial peak and AUC TG were analyzed for dose
comparison by a linear mixed effect model, with treat-
ment and baseline values as fixed effects and subject as
a random effect; however, the pharmacokinetic parame-
ters were analyzed on Day 21 using an ANOVA model
with dose level as a factor, and subject as a random ef-
fect. Estimates of the treatment effect of different dose
levels, together with 90% CI were obtained. Log-
transformation was applied prior to the analysis and the
results were back transformed and reported in the ori-
ginal scale. All the above analyses were repeated for sec-
ondary end points. Missing measurements for AUC
were imputed by linear interpolation only if two adjacent
time points had observed data and was set to missing
otherwise. Missing measurements at the end of the time
interval were imputed from the previous time point.
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